Inventor
SHAHROKH ZAHRA
US39 patents
⚠️ This page may combine multiple inventors who share the name “SHAHROKH ZAHRA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
GENENTECH INC
13 patentsUS7122636B1Oct 17, 2006
Antibody fragment-polymer conjugates and uses of same
GENENTECH INC134 citations98
US6468532B1Oct 22, 2002
Methods of treating inflammatory diseases with anti-IL-8 antibody fragment-polymer conjugates
GENENTECH INC95 citations97
US6171586B1Jan 9, 2001
Antibody formulation
GENENTECH INC1,593 citations97
US7842789B2Nov 30, 2010
Antibody fragment-polymer conjugates and uses of same
GENENTECH INC14 citations92
US7507405B2Mar 24, 2009
Antibody fragment-polymer conjugates and uses of same
GENENTECH INC19 citations92
US7214776B2May 8, 2007
Antibody fragment-polymer conjugates and uses of same
GENENTECH INC26 citations92
US7005504B2Feb 28, 2006
Antibody fragment-peg conjugates
GENENTECH INC30 citations92
US6458355B1Oct 1, 2002
Methods of treating inflammatory disease with anti-IL-8 antibody fragment-polymer conjugates
GENENTECH INC50 citations92
US6870033B1Mar 22, 2005
Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies
GENENTECH INC18 citations81
US7741282B2Jun 22, 2010
ApO2 ligand/TRAIL formulations
GENENTECH INC2 citations57
US7741285B2Jun 22, 2010
APO-2 ligand/trail formulations
GENENTECH INC2 citations57
US7842668B1Nov 30, 2010
Apo-2 ligand/trail formulations
GENENTECH INC0 citations46
US7855066B1Dec 21, 2010
Methods for making Apo-2 ligand using divalent metal ions
GENENTECH INC0 citations37
SHIRE HUMAN GENETIC THERAPIES
10 patentsUS7833766B2Nov 16, 2010
Stabilized compositions of proteins having a free thiol moiety
SHIRE HUMAN GENETIC THERAPIES13 citations92
US9220677B2Dec 29, 2015
Methods and compositions for CNS delivery of iduronate-2-sulfatase
SHIRE HUMAN GENETIC THERAPIES16 citations90
US11260112B2Mar 1, 2022
Methods and compositions for CNS delivery of iduronate-2-sulfatase
SHIRE HUMAN GENETIC THERAPIES2 citations83
US10456454B2Oct 29, 2019
CNS delivery of therapeutic agents
SHIRE HUMAN GENETIC THERAPIES6 citations83
US11065308B2Jul 20, 2021
Methods and compositions for CNS delivery of heparan n-sulfatase
SHIRE HUMAN GENETIC THERAPIES6 citations82
US11471516B2Oct 18, 2022
CNS delivery of therapeutic agents
SHIRE HUMAN GENETIC THERAPIES1 citations72
US10660944B2May 26, 2020
Stable formulations for CNS delivery of arylsulfatase A
SHIRE HUMAN GENETIC THERAPIES5 citations68
US10646554B2May 12, 2020
Methods and compositions for CNS delivery of arylsulfatase A
SHIRE HUMAN GENETIC THERAPIES0 citations60
US9694057B2Jul 4, 2017
Stabilized compositions of proteins having a free thiol moiety
SHIRE HUMAN GENETIC THERAPIES0 citations51
US9072785B2Jul 7, 2015
Stabilized compositions of proteins having a free thiol moiety
SHIRE HUMAN GENETIC THERAPIES0 citations51
TAKEDA PHARMACEUTICALS CO
4 patentsUS12409210B2Sep 9, 2025
CNS delivery of therapeutic agents
TAKEDA PHARMACEUTICALS CO0 citations72
US12121569B2Oct 22, 2024
Methods and compositions for CNS delivery of iduronate-2-sulfatase
TAKEDA PHARMACEUTICALS CO0 citations72
US12161702B2Dec 10, 2024
Methods and compositions for CNS delivery of heparan N-sulfatase
TAKEDA PHARMACEUTICALS CO0 citations71
US12168041B2Dec 17, 2024
Methods and compositions for CNS delivery of arylsulfatase A
TAKEDA PHARMACEUTICALS CO0 citations60
KINIKSA PHARMACEUTICALS LTD
3 patentsUS11141479B2Oct 12, 2021
Stable anti-OSMR antibody formulation
KINIKSA PHARMACEUTICALS LTD0 citations59
US10493149B2Dec 3, 2019
Stable anti-OSMR antibody formulation
KINIKSA PHARMACEUTICALS LTD0 citations47
US10391170B2Aug 27, 2019
Stable anti-OSMR antibody formulation
KINIKSA PHARMACEUTICALS LTD0 citations47